In Vivo Large Scale Mapping Of Protein Turnover In The Human Cerebrospinal Fluid
暂无分享,去创建一个
S. Lehmann | J. Colinge | O. Hanon | A. Gabelle | J. Vialaret | J. Cristol | C. Hirtz | E. Cornillot | L. Bauchet | G. Combes | S. Badiou | M. Corre | Maxence Ory | Marine Le Corre
[1] Lindsay K. Pino,et al. The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. , 2020, Mass spectrometry reviews.
[2] Monocyte Differentiation Antigen CD14 , 2020, Definitions.
[3] Martin Eisenacher,et al. Characterization of Cerebrospinal Fluid via Data-Independent Acquisition Mass Spectrometry. , 2018, Journal of proteome research.
[4] P. Lescuyer,et al. Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods , 2018, Critical reviews in clinical laboratory sciences.
[5] R. Bateman,et al. Erratum: Tau Kinetics in Neurons and the Human Central Nervous System (Neuron (2018) 97(6) (1284–1298.e7)(S0896627318301363)(10.1016/j.neuron.2018.02.015)) , 2018 .
[6] R. Bateman,et al. Tau Kinetics in Neurons and the Human Central Nervous System , 2018, Neuron.
[7] J. Iliff,et al. The Emerging Relationship Between Interstitial Fluid–Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep , 2018, Biological Psychiatry.
[8] Birgit Schilling,et al. Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques , 2017, Expert review of proteomics.
[9] R. Sadygov,et al. Gaussian Process Modeling of Protein Turnover. , 2016, Journal of proteome research.
[10] R. Beynon,et al. Proteome Dynamics: Tissue Variation in the Kinetics of Proteostasis in Intact Animals* , 2016, Molecular & Cellular Proteomics.
[11] A. Labarga,et al. Toward defining the anatomo‐proteomic puzzle of the human brain: An integrative analysis , 2015, Proteomics. Clinical applications.
[12] L. Bernstein,et al. Plasma Transthyretin as a Biomarker of Lean Body Mass and Catabolic States , 2015, Advances in nutrition.
[13] R. Bateman,et al. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. , 2015, The Journal of clinical investigation.
[14] Brian J. Bleakley,et al. Abstract 353: Characterization Of Human Plasma Proteome Dynamics Using Deuterium Oxide , 2014 .
[15] Edward Lau,et al. Protein kinetic signatures of the remodeling heart following isoproterenol stimulation. , 2014, The Journal of clinical investigation.
[16] C. Jack,et al. Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.
[17] Christoph H Borchers,et al. Method and platform standardization in MRM-based quantitative plasma proteomics. , 2013, Journal of proteomics.
[18] Aditi Chatterjee,et al. Plasma Proteome Database as a resource for proteomics research: 2014 update , 2013, Nucleic Acids Res..
[19] H. Zou,et al. A six-plex proteome quantification strategy reveals the dynamics of protein turnover , 2013, Scientific Reports.
[20] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[21] M. Krüger,et al. Stable Isotope Labeling in Zebrafish Allows in Vivo Monitoring of Cardiac Morphogenesis* , 2013, Molecular & Cellular Proteomics.
[22] R. Beynon,et al. Proteome Dynamics: Revisiting Turnover with a Global Perspective* , 2012, Molecular & Cellular Proteomics.
[23] Iain S. Young,et al. A proteomics strategy for determining the synthesis and degradation rates of individual proteins in fish. , 2012, Journal of proteomics.
[24] Norman E. Davey,et al. Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins , 2012, Cell.
[25] D. Holtzman,et al. In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS , 2012, PloS one.
[26] S. Guan,et al. Compartment modeling for mammalian protein turnover studies by stable isotope metabolic labeling. , 2012, Analytical chemistry.
[27] M. Doherty,et al. Proteomics moves from expression to turnover: update and future perspective , 2011, Expert review of proteomics.
[28] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[29] S. Guan,et al. Analysis of proteome dynamics in the mouse brain , 2010, Proceedings of the National Academy of Sciences.
[30] K. Nair,et al. Impact of type 1 diabetes and insulin treatment on plasma levels and fractional synthesis rate of retinol-binding protein 4. , 2009, The Journal of clinical endocrinology and metabolism.
[31] Randall J Bateman,et al. A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.
[32] Sylvain Lehmann,et al. Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers , 2008, Proteomics. Clinical applications.
[33] E. Tsilibary,et al. Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP , 2007, Neurobiology of Disease.
[34] David M Holtzman,et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.
[35] K. Nair,et al. In vivo measurement of synthesis rate of multiple plasma proteins in humans. , 2006, American journal of physiology. Endocrinology and metabolism.
[36] R. Veerhuis,et al. Microglia kill amyloid-&bgr;1-42 damaged neurons by a CD14-dependent process , 2004, NeuroReport.
[37] J. C. Price,et al. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. , 2012, Analytical biochemistry.
[38] Anna Kinsey,et al. Plasma transthyretin as a candidate marker for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[39] J. Waterlow. Whole-body protein turnover in humans--past, present, and future. , 1995, Annual review of nutrition.